On 1st November 2021, representatives from across the UK cell and gene therapy community came together to discuss the UK’s leadership in cell and gene therapy and how this experience can be leveraged to inform future best practice and ensure system readiness for routine ATMP clinical adoption.This document summarises the key findings and conclusions from the workshop.